Exhibits several functions, including fibronectin binding activity; integrin binding activity; and laminin binding activity. Involved in several processes, including maternal process involved in female pregnancy; positive regulation of epithelial cell migration; and regulation of cell projection organization. Localizes to several cellular components, including growth cone filopodium; integrin alpha3-beta1 complex; and perinuclear region of cytoplasm. Biomarker of glomerulonephritis and myocardial infarction. Orthologous to human ITGA3 (integrin subunit alpha 3); PARTICIPATES IN altered Reelin signaling pathway; integrin mediated signaling pathway; interleukin-23 signaling pathway; INTERACTS WITH 1-naphthyl isothiocyanate; 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine; all-trans-retinoic acid.
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ITGA3 mRNA
notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 mRNA], notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ITGA3 mRNA
[Disulfiram binds to Copper] which results in increased expression of ITGA3 mRNA, [NSC 689534 binds to Copper] which results in increased expression of ITGA3 mRNA
[Disulfiram binds to Copper] which results in increased expression of ITGA3 mRNA, [NSC 689534 binds to Copper] which results in increased expression of ITGA3 mRNA
notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 mRNA], notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ITGA3 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA3 mRNA
notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 mRNA], notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ITGA3 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA3 mRNA
NCF1 protein inhibits the reaction [pirinixic acid results in decreased expression of ITGA3 mRNA], PPARA protein promotes the reaction [pirinixic acid results in decreased expression of ITGA3 mRNA]
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA3 mRNA
notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGA3 mRNA], notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGA3 protein]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
